Key statistics dashboard for Pulmonx Corporation (LUNG). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System.
Stock Data
| Price | $2.07 |
| Market Cap | $87M |
| Enterprise Value | $87.8M |
| Beta | 0.19 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.72 |
| Price / Book | 2.13 |
| P/S | 0.96 |
| EV/EBITDA | -2.04 |
| EV/Sales | 1.00 |
| EV/FCF | -2.86 |
| P/FCF | -2.73 |
| Earnings Yield | -55.10% |
| FCF Yield | -35.08% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 77.06% |
| EBIT Margin | -50.03% |
| EBITDA Margin | -49.24% |
| Operating Margin | -52.96% |
| Net Margin | -55.03% |
| Return on Equity | -96.66% |
| Return on Assets | -41.94% |
| Return on Invested Capital | -48.39% |
| Return on Capital Employed | -49.09% |
Financial Health
| Current Ratio | 4.32 |
| Quick Ratio | 3.52 |
| Cash Ratio | 2.74 |
| Debt / Equity | 1.43 |
| Debt / Assets | 48.99% |
| Net Debt / EBITDA | -0.01 |
| Interest Coverage | -12.29 |
Per-Share Data
| Revenue per share | 2.07 |
| Book Value per share | 0.93 |
| Cash per share | 1.32 |
| FCF per share | -0.73 |
| Tangible Book Value per share | 0.87 |
| Dividend per share | 0.00 |
Related companies: ACRV · ASRT · EDAP · HYPR · IMUX · PMVP · RLMD
Explore sector: Healthcare · Medical - Devices
More sections of LUNG: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks